Image may be NSFW.
Clik here to view.
Shares in Ocular Therapeutix (NSDQ:OCUL) fell last week after the company revealed that it received another letter from the FDA about issues spotted by the regulatory agency during a pre-approval inspection of a manufacturing plant.
This isn’t the first time that the company has dealt with manufacturing issues. In July last year, the FDA denied approval for Ocular’s hydrogel plug, Dextenza, after it discovered “deficiencies in manufacturing process and controls” in a pre-new drug application approval inspection.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocular Therapeutix faces more manufacturing problems as FDA decision deadline looms appeared first on MassDevice.
